
Survodutide

Investigational · not FDA-approved.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Survodutide (BI 456906) is an investigational medicine that activates glucagon and GLP-1 receptors. Researchers are studying it for obesity and MASH, a form of metabolic liver disease with inflammation. Phase 3 development is underway; it is not FDA-approved. [1]

02 Potential benefits

Trials have studied weight reduction and liver-biopsy outcomes in MASH. A phase 2 MASH trial found more improvement without worsening fibrosis than placebo. These are separate outcomes; they do not establish a cure, prevention of liver failure or longer survival. [1]

03 Evidence & its limits

Weight loss and liver improvement are different questions. A liver-biopsy result does not by itself establish prevention of liver failure or longer survival. Gastrointestinal side effects matter, and trial results do not verify the contents or safety of online products sold under this name. [1]

04 Risks & unknowns

Nausea, diarrhea and vomiting were more common than placebo in the MASH trial. Serious adverse events also occurred. Study-specific rates cannot be generalized to every population or regimen. Larger and longer studies are needed; online products are not validated by trial results. [1]

05 Status & scope

Phase 3 development is underway; it is not FDA-approved. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] Randomized phase 2 obesity trial — 2024
[3] NEJM: phase 2 randomized MASH and fibrosis trial — 2024
[4] Boehringer Ingelheim: SYNCHRONIZE-2 phase 3 update — October 1, 2026

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.